Zomedica is a veterinary diagnostics and medical device company focused on creating innovative products that improve both patient health and standards of care. The company examines the unmet needs of clinical veterinarians in order to design products for companion animals (canine, feline, equine, etc.). Zomedica is building a diversified portfolio of products centered around the discovery, development, and commercialization of innovative drugs alongside novel drug delivery systems, devices, and diagnostics. The company is headquartered in Ann Arbor, Michigan and was founded in 2015 by Jerry Solensky.
TRUFORMA is Zomedica’s biosensor platform designed to assist practitioners in the diagnosis of complex conditions. Protected by approximately 70 issued and pending patents, the TRUFORMA platform uses Bulk Acoustic Wave (“BAW”) technology, developed by Qorvo, to provide a non-optical and fluorescence-free detection system for use at the point-of-care. BAW technology, also used in cell phones, radar, and communications systems, is extremely reliable and precise. TRUFORMA is specifically designed to diagnose thyroid disease in dogs and cats, and adrenal disease in dogs. This biosensor platform can be installed entirely remotely and provides test results within 20-30 minutes.
Investor Overview | Zomedica Corp.
TRUFORMA - Zomedica
TRUFORMATM In-Clinic Biosensor Platform Technology
April 3, 2020
Zomedica Sets March 30, 2021 as Expected Commercialization Date for TRUFORMATM
November 13, 2020